Cupps Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Cupps Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$2.22M	Buy	43,902 +5	+0%	+$249	0.96%	27
2016 Q2	$2M	Sell	43,897 -54,738	-55%	-$2.52M	0.52%	77
2016 Q1	$3.9M	Sell	98,635 -8,575	-8%	-$340K	0.74%	54
2015 Q4	$6.06M	Buy	107,210 +47,745	+80%	+$2.43M	0.85%	44
2015 Q3	$2.37M	Buy	+59,465	New	+$2.87M	0.31%	93
2013 Q3	–	Sell	-431,896	Closed	-$5.78M	–	201
2013 Q2	$5.78M	Buy	+431,896	New	+$5.31M	0.46%	62

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Cupps Capital Management's NBIX Position: Q3 2016 in Review

Cupps Capital Management increased its Neurocrine Biosciences (NBIX) stake by 0.01% in Q3 2016, buying an estimated $249 and bringing the position to 43,902 shares worth $2.22M. The position accounts for 0.96% of the portfolio, ranked #27.

Cupps Capital Management first reported a position in NBIX in Q2 2013 and has held it in 6 quarters since. The position peaked at $6.06M in Q4 2015. 245 funds tracked by Wall St. Rank hold NBIX as of Q3 2016.

Cupps Capital Management held 43,902 shares of Neurocrine Biosciences worth $2.22M as of Q3 2016.
Cupps Capital Management bought 5 Neurocrine Biosciences shares in Q3 2016, an estimated $249.
Neurocrine Biosciences made up 0.96% of Cupps Capital Management's portfolio in Q3 2016, its #27 holding.
Cupps Capital Management first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 6 quarters since.
Cupps Capital Management's Neurocrine Biosciences position peaked at $6.06M in Q4 2015.
245 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2016.

Based on Cupps Capital Management's 13F filing for Q3 2016, filed 11 Oct 2016.